Compounds > ritodrine hydrochloride
Page last updated: 2024-11-10

ritodrine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3040551
CHEMBL ID1376064
SCHEMBL ID3677546
MeSH IDM0475060

Synonyms (72)

Synonym
MLS001148127
52447-11-7
EU-0101041
einecs 245-514-8
erythro-p-hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol hydrochloride
benzyl alcohol, p-hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)-, hydrochloride, erythro-
benzenemethanol, 4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)-, hydrochloride, (r*,s*)-
(r*,s*)-4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)benzyl alcohol hydrochloride
utopar
nsc 291565
benzenemethanol, 4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)-, hydrochloride, (r*,s*)-(+-)-
yutopar
(+-)-erythro-1-(p-hydroxyphenyl)-2-(2-(p-hydroxyphenyl)ethylamino)-1-propanol
(+-)-ritodrine hydrochloride
pre-par
nsc-291565
ritodrine hydrochloride
nsc291565
MLS001333192
smr000326750
MLS000859888
NCGC00094326-01
MLS001333191
n-(p-hydroxyphenethyl)-4-hydroxynorephedrine hydrochloride
R 0758
hydrochloride, ritodrine
dtxcid6025438
esj56q60gc ,
ritodrine hydrochloride [usan:usp:jan]
ritodrine hydrochloride in dextrose 5% in plastic container
unii-esj56q60gc
du 21220; miolene; nsc 291565
ritodrine hydrochloride (yutopar)
BCP0726000243
LP01041
ritodrine hydrochloride [mi]
luteonin
ritodrine hydrochloride [orange book]
ritodrine hydrochloride [mart.]
erythro-p-hydroxy-.alpha.-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol hydrochloride
ritodrine hydrochloride [who-dd]
ritodrine hydrochloride [usp-rs]
ritodrine hydrochloride [usp impurity]
ritodrine hydrochloride [jan]
ritodrine hydrochloride [vandf]
ritodrine hydrochloride [usan]
benzenemethanol, 4-hydroxy-.alpha.-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)-, hydrochloride, (r*,s*)-
S2533
CCG-222345
ritodrine (hydrochloride)
HY-B0452
MLS006011162
SCHEMBL3677546
NCGC00261726-01
tox21_501041
REGID_FOR_CID_3040551
AKOS024374986
CHEMBL1376064
DTXSID00200447
sr-01000076101
SR-01000076101-2
SR-01000076101-4
SW219275-1
Q27277341
4-[2-[[(1s,2r)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol;hydrochloride
4-(2-((1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)amino)ethyl)phenol hydrochloride
benzenemethanol, 4-hydroxy-alpha-[(1r)-1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, hydrochloride (1:1), (alphas)-rel-
rel-4-(2-((1s,2r)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol hydrochloride
ritodrine hydrochloride (usp impurity)
ritodrine hydrochloride (mart.)
ritodrine hydrochloride (usp-rs)
(1rs,2sr)-1-(4-hydroxyphenyl)-2-((2-(4-hydroxyphenyl)ethyl)amino)propan-1-ol monohydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency2.14680.01846.806014.1254AID624417; AID743262
GLS proteinHomo sapiens (human)Potency22.38720.35487.935539.8107AID624170
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.53080.001530.607315,848.9004AID1224821
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.94330.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency9.75930.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency1.58490.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.38 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index101.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Benign Neoplasms
[description not available]		03.0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0310